MECP2 and lymphoma: In addition, amore recent study from Mavragani et al., demonstrated a reduced level of LINE-1 promoter methylation along with increased DNMT3B, DNMT1, and MeCP2 in SjS patients with low risk for developing lymphoma compared to both SjS-lymphoma patients and sicca controls [65].